Yvette Bordelon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yvette Bordelon has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Beate Ritz
University of California
2 shared publications - Jeff M. Bronstein
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, USA
2 shared publications - Kimberly C. Paul
Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, USA
2 shared publications - Nader Pouratian
Department of Neurological Surgery, University of Texas Southwestern, United States
2 shared publications - Yu-Hsuan Chuang
Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA
2 shared publications - Adriano Alves Pereira
Universidade Federal de Uberlândia, Brasil
1 shared publication
Latest Publications
- Open Access
- 1 October 2024
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 14 (5) , e200344
Racial Disparities in Time to Huntington Disease Diagnosis in North America
There are well-documented racial and ethnic disparities in access to neurologic care and disease-specific outcomes. Although contemporary clinical and neurogenetic understanding of Huntington disease (HD) is thanks to a decades-long study of a Venezuelan cohort, there are a limited number of studies that have evaluated racial and ethnic disparities in HD. The goal of this study was to evaluate disparities in time from symptom onset to time of diagnosis of HD. Using the ENROLL-HD periodic data set 5 (PDS5), we performed sequential multivariate linear regressions to evaluate sociodemographic factors associated with disparities in time to diagnosis (TTD) for gene-positive individuals (CAG repeats 36+) in the North America region. Sensitivity analyses included imputed multivariate regression analysis of individuals with a total motor score (TMS) of 10 or higher and those with 40+ CAG repeats. We also used descriptive statistics to present TTD data in other ENROLL-HD participating regions. Among 4717 gene-positive participants in the North American region, 89.5% identified as White, 3.4% as Hispanic or Latino, and 2.3% as African American/Black. The average TTD in the group was 3.78. When adjusting for clinical and sociodemographic variables, Black participants were diagnosed with HD 1 year later than White participants (p < 0.05). Additional factors associated with a later diagnosis included psychiatric symptoms as initial HD symptom, unemployment during baseline ENROLL visit, and higher educational attainment. Sensitivity analysis of gene-positive (36+ CAG) participants with a TMS of 10 or higher and of those with 40+ CAG repeats yielded similar findings. Across multiple statistical models, Black ENROLL-HD participants were diagnosed with HD 1 year later than White participants. Clinical factors suggesting a delay in HD diagnosis included psychiatric symptoms at disease onset and a negative family history of HD. Unemployment during baseline visit and higher educational attainment were sociodemographic factors suggestive of a later diagnosis. Additional multicenter qualitative and quantitative studies are needed to better understand reasons for delays in HD diagnosis among Black individuals, and the role of social and structural determinants of health in obtaining a timely HD diagnosis.
- 1 October 2024
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 14 (5) , e200344
Open AccessRacial Disparities in Time to Huntington Disease Diagnosis in North America
There are well-documented racial and ethnic disparities in access to neurologic care and disease-specific outcomes. Although contemporary clinical and neurogenetic understanding of Huntington disease (HD) is thanks to a decades-long study of a Venezuelan cohort, there are a limited number of studies that have evaluated racial and ethnic disparities in HD. The goal of this study was to evaluate disparities in time from symptom onset to time of diagnosis of HD. Using the ENROLL-HD periodic data set 5 (PDS5), we performed sequential multivariate linear regressions to evaluate sociodemographic factors associated with disparities in time to diagnosis (TTD) for gene-positive individuals (CAG repeats 36+) in the North America region. Sensitivity analyses included imputed multivariate regression analysis of individuals with a total motor score (TMS) of 10 or higher and those with 40+ CAG repeats. We also used descriptive statistics to present TTD data in other ENROLL-HD participating regions. Among 4717 gene-positive participants in the North American region, 89.5% identified as White, 3.4% as Hispanic or Latino, and 2.3% as African American/Black. The average TTD in the group was 3.78. When adjusting for clinical and sociodemographic variables, Black participants were diagnosed with HD 1 year later than White participants (p < 0.05). Additional factors associated with a later diagnosis included psychiatric symptoms as initial HD symptom, unemployment during baseline ENROLL visit, and higher educational attainment. Sensitivity analysis of gene-positive (36+ CAG) participants with a TMS of 10 or higher and of those with 40+ CAG repeats yielded similar findings. Across multiple statistical models, Black ENROLL-HD participants were diagnosed with HD 1 year later than White participants. Clinical factors suggesting a delay in HD diagnosis included psychiatric symptoms at disease onset and a negative family history of HD. Unemployment during baseline visit and higher educational attainment were sociodemographic factors suggestive of a later diagnosis. Additional multicenter qualitative and quantitative studies are needed to better understand reasons for delays in HD diagnosis among Black individuals, and the role of social and structural determinants of health in obtaining a timely HD diagnosis.
- Open Access
- 10 March 2022
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 12 (1) , 5
Vim-Thalamic Deep Brain Stimulation for Cervical Dystonia and Upper-Limb Tremor: Quantification by Markerless-3D Kinematics and Accelerometry
Background: Deep Brain Stimulation (DBS) for dystonia is usually targeted to the globus pallidus internus (GPi), though stimulation of the ventral-intermediate nucleus of the thalamus (Vim) can be an effective treatment for phasic components of dystonia including tremor. We report on a patient who developed a syndrome of bilateral upper limb postural and action tremor and progressive cervical dystonia with both phasic and tonic components which were responsive to Vim DBS. We characterize and quantify this effect using markerless-3D-kinematics combined with accelerometry. Methods: Stereo videography was used to record our subject in 3D. The DeepBehavior toolbox was applied to obtain timeseries of joint position for kinematic analysis [1]. Accelerometry was performed simultaneously for comparison with prior literature. Results: Bilateral Vim DBS improved both dystonic tremor magnitude and tonic posturing. DBS of the hemisphere contralateral to the direction of dystonic head rotation (left Vim) had greater efficacy. Assessment of tremor magnitude by 3D-kinematics was concordant with accelerometry and was able to quantify tonic dystonic posturing. Discussion: In this case, Vim DBS treated both cervical dystonic tremor and dystonic posturing. Markerless-3D-kinematics should be further studied as a method of quantifying and characterizing tremor and dystonia.
- 10 March 2022
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 12 (1) , 5
Open AccessVim-Thalamic Deep Brain Stimulation for Cervical Dystonia and Upper-Limb Tremor: Quantification by Markerless-3D Kinematics and Accelerometry
Background: Deep Brain Stimulation (DBS) for dystonia is usually targeted to the globus pallidus internus (GPi), though stimulation of the ventral-intermediate nucleus of the thalamus (Vim) can be an effective treatment for phasic components of dystonia including tremor. We report on a patient who developed a syndrome of bilateral upper limb postural and action tremor and progressive cervical dystonia with both phasic and tonic components which were responsive to Vim DBS. We characterize and quantify this effect using markerless-3D-kinematics combined with accelerometry. Methods: Stereo videography was used to record our subject in 3D. The DeepBehavior toolbox was applied to obtain timeseries of joint position for kinematic analysis [1]. Accelerometry was performed simultaneously for comparison with prior literature. Results: Bilateral Vim DBS improved both dystonic tremor magnitude and tonic posturing. DBS of the hemisphere contralateral to the direction of dystonic head rotation (left Vim) had greater efficacy. Assessment of tremor magnitude by 3D-kinematics was concordant with accelerometry and was able to quantify tonic dystonic posturing. Discussion: In this case, Vim DBS treated both cervical dystonic tremor and dystonic posturing. Markerless-3D-kinematics should be further studied as a method of quantifying and characterizing tremor and dystonia.
- 1 May 2019
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 62, 57-61
Genetic variants in nicotinic receptors and smoking cessation in Parkinson's disease
- 1 May 2019
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 62, 57-61
Genetic variants in nicotinic receptors and smoking cessation in Parkinson's disease
- Open Access
- 30 August 2017
- Published by Springer Nature in Genome Medicine
- Vol. 9 (1) , 1-12
Parkinson’s disease is associated with DNA methylation levels in human blood and saliva
Several articles suggest that DNA methylation levels in blood relate to Parkinson’s disease (PD) but there is a need for a large-scale study that involves suitable population based controls. The purposes of the study were: (1) to study whether PD status is associated with DNA methylation levels in blood/saliva; (2) to study whether observed associations relate to blood cell types; and (3) to characterize genome-wide significant markers (“CpGs”) and clusters of CpGs (co-methylation modules) in terms of biological pathways. In a population-based case control study of PD, we studied blood samples from 335 PD cases and 237 controls and saliva samples from another 128 cases and 131 controls. DNA methylation data were generated from over 486,000 CpGs using the Illumina Infinium array. We identified modules of CpGs (clusters) using weighted correlation network analysis (WGCNA). Our cross-sectional analysis of blood identified 82 genome-wide significant CpGs (including cg02489202 in LARS2 p = 8.3 × 10–11 and cg04772575 in ABCB9 p = 4.3 × 10–10). Three out of six PD related co-methylation modules in blood were significantly enriched with immune system related genes. Our analysis of saliva identified five significant CpGs. PD-related CpGs are located near genes that relate to mitochondrial function, neuronal projection, cytoskeleton organization, systemic immune response, and iron handling. This study demonstrates that: (1) PD status has a profound association with DNA methylation levels in blood and saliva; and (2) the most significant PD-related changes reflect changes in blood cell composition. Overall, this study highlights the role of the immune system in PD etiology but future research will need to address the causal structure of these relationships.
- 30 August 2017
- Published by Springer Nature in Genome Medicine
- Vol. 9 (1) , 1-12
Open AccessParkinson’s disease is associated with DNA methylation levels in human blood and saliva
Several articles suggest that DNA methylation levels in blood relate to Parkinson’s disease (PD) but there is a need for a large-scale study that involves suitable population based controls. The purposes of the study were: (1) to study whether PD status is associated with DNA methylation levels in blood/saliva; (2) to study whether observed associations relate to blood cell types; and (3) to characterize genome-wide significant markers (“CpGs”) and clusters of CpGs (co-methylation modules) in terms of biological pathways. In a population-based case control study of PD, we studied blood samples from 335 PD cases and 237 controls and saliva samples from another 128 cases and 131 controls. DNA methylation data were generated from over 486,000 CpGs using the Illumina Infinium array. We identified modules of CpGs (clusters) using weighted correlation network analysis (WGCNA). Our cross-sectional analysis of blood identified 82 genome-wide significant CpGs (including cg02489202 in LARS2 p = 8.3 × 10–11 and cg04772575 in ABCB9 p = 4.3 × 10–10). Three out of six PD related co-methylation modules in blood were significantly enriched with immune system related genes. Our analysis of saliva identified five significant CpGs. PD-related CpGs are located near genes that relate to mitochondrial function, neuronal projection, cytoskeleton organization, systemic immune response, and iron handling. This study demonstrates that: (1) PD status has a profound association with DNA methylation levels in blood and saliva; and (2) the most significant PD-related changes reflect changes in blood cell composition. Overall, this study highlights the role of the immune system in PD etiology but future research will need to address the causal structure of these relationships.
- Open Access
- 30 December 2016
- Published by Springer Nature in BioMedical Engineering OnLine
- Vol. 15 (1) , 169
Feature visualization and classification for the discrimination between individuals with Parkinson’s disease under levodopa and DBS treatments
Over the years, a number of distinct treatments have been adopted for the management of the motor symptoms of Parkinson’s disease (PD), including pharmacologic therapies and deep brain stimulation (DBS). Efficacy is most often evaluated by subjective assessments, which are prone to error and dependent on the experience of the examiner. Our goal was to identify an objective means of assessing response to therapy. In this study, we employed objective analyses in order to visualize and identify differences between three groups: healthy control (N = 10), subjects with PD treated with DBS (N = 12), and subjects with PD treated with levodopa (N = 16). Subjects were assessed during execution of three dynamic tasks (finger taps, finger to nose, supination and pronation) and a static task (extended arm with no active movement). Measurements were acquired with two pairs of inertial and electromyographic sensors. Feature extraction was applied to estimate the relevant information from the data after which the high-dimensional feature space was reduced to a two-dimensional space using the nonlinear Sammon’s map. Non-parametric analysis of variance was employed for the verification of relevant statistical differences among the groups (p < 0.05). In addition, K-fold cross-validation for discriminant analysis based on Gaussian Finite Mixture Modeling was employed for data classification. The results showed visual and statistical differences for all groups and conditions (i.e., static and dynamic tasks). The employed methods were successful for the discrimination of the groups. Classification accuracy was 81 ± 6% (mean ± standard deviation) and 71 ± 8%, for training and test groups respectively. This research showed the discrimination between healthy and diseased groups conditions. The methods were also able to discriminate individuals with PD treated with DBS and levodopa. These methods enable objective characterization and visualization of features extracted from inertial and electromyographic sensors for different groups.
- 30 December 2016
- Published by Springer Nature in BioMedical Engineering OnLine
- Vol. 15 (1) , 169
Open AccessFeature visualization and classification for the discrimination between individuals with Parkinson’s disease under levodopa and DBS treatments
Over the years, a number of distinct treatments have been adopted for the management of the motor symptoms of Parkinson’s disease (PD), including pharmacologic therapies and deep brain stimulation (DBS). Efficacy is most often evaluated by subjective assessments, which are prone to error and dependent on the experience of the examiner. Our goal was to identify an objective means of assessing response to therapy. In this study, we employed objective analyses in order to visualize and identify differences between three groups: healthy control (N = 10), subjects with PD treated with DBS (N = 12), and subjects with PD treated with levodopa (N = 16). Subjects were assessed during execution of three dynamic tasks (finger taps, finger to nose, supination and pronation) and a static task (extended arm with no active movement). Measurements were acquired with two pairs of inertial and electromyographic sensors. Feature extraction was applied to estimate the relevant information from the data after which the high-dimensional feature space was reduced to a two-dimensional space using the nonlinear Sammon’s map. Non-parametric analysis of variance was employed for the verification of relevant statistical differences among the groups (p < 0.05). In addition, K-fold cross-validation for discriminant analysis based on Gaussian Finite Mixture Modeling was employed for data classification. The results showed visual and statistical differences for all groups and conditions (i.e., static and dynamic tasks). The employed methods were successful for the discrimination of the groups. Classification accuracy was 81 ± 6% (mean ± standard deviation) and 71 ± 8%, for training and test groups respectively. This research showed the discrimination between healthy and diseased groups conditions. The methods were also able to discriminate individuals with PD treated with DBS and levodopa. These methods enable objective characterization and visualization of features extracted from inertial and electromyographic sensors for different groups.
- Open Access
- 1 November 2016
- Published by Elsevier in Neurobiology of Aging
- Vol. 47, 201-209
Widespread white matter and conduction defects in PSEN1-related spastic paraparesis
- 1 November 2016
- Published by Elsevier in Neurobiology of Aging
- Vol. 47, 201-209
Open AccessWidespread white matter and conduction defects in PSEN1-related spastic paraparesis
- 1 January 2016
- Published by Elsevier
- p. 301-315
A New Neuroanatomy of Basal Ganglia Circuitry
- 1 April 2014
- Published by Georg Thieme Verlag KG in Seminars in Neurology
- Vol. 34 (02) , 119-120
Atypical Parkinsonian Disorders
It has been exactly 50 years since the publication of the seminal article by John Steele, J. Clifford Richardson, and Jerzy Olszewski describing the clinical and pathologic characteristics of a neurodegenerative disease they named “progressive supranuclear palsy” (but still known to many as the Steele–Richardson–Olszewski syndrome). Since that time, an enormous amount of progress has been made in our understanding of this and similar disorders, commonly referred to as atypical parkinsonian disorders. Because there has not been an issue of Seminars in Neurology dedicated to this topic, we felt that this year—2014—the 50th anniversary of the original publication by Steele, Richardson, and Olszewski, was an appropriate time to provide a comprehensive update of these disorders. We are pleased to have the original paper reprinted in this issue in commemoration of their landmark article. This issue appropriately begins with a historical perspective by John Steele himself. Next, we present authoritative clinical reviews on both tauopathy and synucleinopathy diseases within the atypical parkinsonian disorders (APDs), including monographs on progressive supranuclear palsy (PSP) by Larry Golbe, corticobasal syndrome (CBS) by Ana Grijalvo-Perez and Irene Litvan, multiple system atrophy (MSA) by Tasneem Peeraully, dementia with Lewy bodies (DLB) by Katie Mayo and Yvette Bordelon, and frontotemporal lobar degenerations (FTLD) by Elissaios Karageorgiou and Bruce Miller. These reviews include updated clinical diagnostic criteria, discussions of the presumed pathophysiological mechanisms of disease, and up-to-date summaries of current treatments. Next, we present a review on the role of brain imaging modalities in the diagnosis of APDs by Florian Holtbernd and David Eidelberg, and another on the neuropathology of the synucleinopathies by Jean-Paul Vonsattel and Etty Cortes Ramirez (the neuropathological features of PSP being already covered in the original Steele et al article). We then feature a review of the genetic contributions to these disorders by Dan Geschwind and colleagues, with insightful discussion of how rapidly expanding genomics approaches can aid not only in diagnosis and classification, but also in the treatment of these APDs. And finally we close the issue with an article that summarizes the latest data on clinical trials for these various disorders by Richard Tsai and Adam Boxer; they provide a window into the future of drug development and the rapid progress we will see in the next several years. We are delighted to have a complement of such distinguished leaders in the field contributing to this issue. Although the occurrence of APDs is rare when compared with Alzheimer disease and Parkinson disease, the first and second most common neurodegenerative disorders, respectively, research in this area will provide critical information to guide therapeutic strategies for all related disorders. This is due to the significant overlap in pathophysiologic and genetic contributions to these diseases. The recognition that all of these disorders are characterized by protein misfolding, be it aggregated tau, α-synuclein, or other proteins, has unified research efforts further. These advances will continue to fuel discovery of treatments targeted at the genetic and pathologic levels, including mechanisms integral to tau and α-synuclein processing. In addition, clinical diagnosis of these rare disorders will continue to improve with greater awareness, refined criteria and improved diagnostic testing. This is extremely important, knowing that many patients spend several years with diagnostic uncertainty. The number of clinical trials focusing on APDs has increased over the past several years, perhaps because of the advantages that they represent more homogeneous populations, the clinical diagnostic criteria are better defined, and the underlying proteinopathy has been well characterized. Thus, tau-specific agents can be studied in the pure tauopathy syndromes (PSP and CBD), and when found to be effective could easily benefit other tau-associated disorders like Alzheimer disease or FTLD. As treatments emerge, early diagnosis will lead to earlier targeted therapies and significantly benefit patients and families dealing with these diseases. We believe that we are at a turning point in the field of investigation in these atypical parkinsonian disorders. The growth in understanding of the overlapping pathologic and genetic contributions of these diseases coupled with improved diagnostic testing and clinical diagnostic criteria have set the stage for accelerated development of effective symptomatic as well as disease-modifying therapies. We anticipate that we will not have to wait another 50 years before we witness radical advances in the treatment of individuals and families dealing with these diseases, as therapeutic pipelines mature and produce meaningful treatments. A special thanks goes to the Editor-in-Chief, David Greer, for allowing us to provide an update on the APDs and for obtaining permission to reprint Dr. Steele's original article. We thank all of our authors for their outstanding contributions and we hope that you enjoy this issue of Seminars in Neurology.
- 1 April 2014
- Published by Georg Thieme Verlag KG in Seminars in Neurology
- Vol. 34 (02) , 119-120
Atypical Parkinsonian Disorders
It has been exactly 50 years since the publication of the seminal article by John Steele, J. Clifford Richardson, and Jerzy Olszewski describing the clinical and pathologic characteristics of a neurodegenerative disease they named “progressive supranuclear palsy” (but still known to many as the Steele–Richardson–Olszewski syndrome). Since that time, an enormous amount of progress has been made in our understanding of this and similar disorders, commonly referred to as atypical parkinsonian disorders. Because there has not been an issue of Seminars in Neurology dedicated to this topic, we felt that this year—2014—the 50th anniversary of the original publication by Steele, Richardson, and Olszewski, was an appropriate time to provide a comprehensive update of these disorders. We are pleased to have the original paper reprinted in this issue in commemoration of their landmark article. This issue appropriately begins with a historical perspective by John Steele himself. Next, we present authoritative clinical reviews on both tauopathy and synucleinopathy diseases within the atypical parkinsonian disorders (APDs), including monographs on progressive supranuclear palsy (PSP) by Larry Golbe, corticobasal syndrome (CBS) by Ana Grijalvo-Perez and Irene Litvan, multiple system atrophy (MSA) by Tasneem Peeraully, dementia with Lewy bodies (DLB) by Katie Mayo and Yvette Bordelon, and frontotemporal lobar degenerations (FTLD) by Elissaios Karageorgiou and Bruce Miller. These reviews include updated clinical diagnostic criteria, discussions of the presumed pathophysiological mechanisms of disease, and up-to-date summaries of current treatments. Next, we present a review on the role of brain imaging modalities in the diagnosis of APDs by Florian Holtbernd and David Eidelberg, and another on the neuropathology of the synucleinopathies by Jean-Paul Vonsattel and Etty Cortes Ramirez (the neuropathological features of PSP being already covered in the original Steele et al article). We then feature a review of the genetic contributions to these disorders by Dan Geschwind and colleagues, with insightful discussion of how rapidly expanding genomics approaches can aid not only in diagnosis and classification, but also in the treatment of these APDs. And finally we close the issue with an article that summarizes the latest data on clinical trials for these various disorders by Richard Tsai and Adam Boxer; they provide a window into the future of drug development and the rapid progress we will see in the next several years. We are delighted to have a complement of such distinguished leaders in the field contributing to this issue. Although the occurrence of APDs is rare when compared with Alzheimer disease and Parkinson disease, the first and second most common neurodegenerative disorders, respectively, research in this area will provide critical information to guide therapeutic strategies for all related disorders. This is due to the significant overlap in pathophysiologic and genetic contributions to these diseases. The recognition that all of these disorders are characterized by protein misfolding, be it aggregated tau, α-synuclein, or other proteins, has unified research efforts further. These advances will continue to fuel discovery of treatments targeted at the genetic and pathologic levels, including mechanisms integral to tau and α-synuclein processing. In addition, clinical diagnosis of these rare disorders will continue to improve with greater awareness, refined criteria and improved diagnostic testing. This is extremely important, knowing that many patients spend several years with diagnostic uncertainty. The number of clinical trials focusing on APDs has increased over the past several years, perhaps because of the advantages that they represent more homogeneous populations, the clinical diagnostic criteria are better defined, and the underlying proteinopathy has been well characterized. Thus, tau-specific agents can be studied in the pure tauopathy syndromes (PSP and CBD), and when found to be effective could easily benefit other tau-associated disorders like Alzheimer disease or FTLD. As treatments emerge, early diagnosis will lead to earlier targeted therapies and significantly benefit patients and families dealing with these diseases. We believe that we are at a turning point in the field of investigation in these atypical parkinsonian disorders. The growth in understanding of the overlapping pathologic and genetic contributions of these diseases coupled with improved diagnostic testing and clinical diagnostic criteria have set the stage for accelerated development of effective symptomatic as well as disease-modifying therapies. We anticipate that we will not have to wait another 50 years before we witness radical advances in the treatment of individuals and families dealing with these diseases, as therapeutic pipelines mature and produce meaningful treatments. A special thanks goes to the Editor-in-Chief, David Greer, for allowing us to provide an update on the APDs and for obtaining permission to reprint Dr. Steele's original article. We thank all of our authors for their outstanding contributions and we hope that you enjoy this issue of Seminars in Neurology.
- 1 November 2013
- Published by Elsevier in Neurologic Clinics
- Vol. 31 (4) , 1085-1094
Clinical Neurogenetics
- 1 November 2013
- Published by Elsevier in Neurologic Clinics
- Vol. 31 (4) , 1085-1094
Clinical Neurogenetics
- Open Access
- 1 January 2011
- Published by Wiley in Parkinson's Disease
- Vol. 2011, 1-6
Medication Responsiveness of Motor Symptoms in a Population-Based Study of Parkinson Disease
We assessed degree of Parkinson disease motor symptom improvement with medication among subjects enrolled in an ongoing, population-based study in Central California. The motor section of the unified Parkinson disease rating scale (UPDRS) was performed on subjects in both OFF and ON medication states, and difference between these scores was used as an indicator of symptomatic benefit. Higher OFF minus ON scores correlated with more severe baseline symptoms. There was equivalent improvement on the motor UPDRS scale for subjects divided according to medication classes used: levodopa alone 7.3 points, levodopa plus other medications 8.5 points, and dopamine agonists but not levodopa 6.1 points. In addition, there was no difference in the magnitude of improvement when subjects were divided according to Parkinson disease subtype, defined as tremor dominant, akinetic-rigid, or mixed. In this community-based sample, these values are within the range of a clinically important difference as defined by previous studies.
- 1 January 2011
- Published by Wiley in Parkinson's Disease
- Vol. 2011, 1-6
Open AccessMedication Responsiveness of Motor Symptoms in a Population-Based Study of Parkinson Disease
We assessed degree of Parkinson disease motor symptom improvement with medication among subjects enrolled in an ongoing, population-based study in Central California. The motor section of the unified Parkinson disease rating scale (UPDRS) was performed on subjects in both OFF and ON medication states, and difference between these scores was used as an indicator of symptomatic benefit. Higher OFF minus ON scores correlated with more severe baseline symptoms. There was equivalent improvement on the motor UPDRS scale for subjects divided according to medication classes used: levodopa alone 7.3 points, levodopa plus other medications 8.5 points, and dopamine agonists but not levodopa 6.1 points. In addition, there was no difference in the magnitude of improvement when subjects were divided according to Parkinson disease subtype, defined as tremor dominant, akinetic-rigid, or mixed. In this community-based sample, these values are within the range of a clinically important difference as defined by previous studies.